Celltrion Healthcare said it has recently hired Thomas Nusbickel, who has worked at multinational drugmakers such as Amgen and Pfizer, as Chief Commercial Officer (CCO) of Celltrion USA.

According to Celltrion Healthcare, new CCO Nusbickel is an expert in sales, marketing, market access, and government affairs in the biopharmaceutical industry and has worked in the industry for more than 30 years.

"Notably, Nusbickel has a high understanding of the U.S. biosimilar industry as he has experience in successfully leading biosimilar businesses at global pharmaceutical companies such as Pfizer," the company said.

Celltrion Healthcare expects to accelerate the expansion of its U.S. business based on Nusbickel's experience and know-how.

Celltrion Healthcare, which entered the U.S. market with Remsima (ingredient: Infliximab) in 2016, acquired Celltrion USA, which holds a U.S. drug distribution license, from Celltrion in August 2022, laying the foundation for direct sales.

As the company is in the early stage of direct sales, the company expects that Nusbickel will establish an optimal strategy for the U.S. market expansion and strengthen the distribution network to sell other biosimilars products such as Vegzelma (ingredient: bevacizumab), Yuflyma (ingredient: adalimumab), and Remsima SC.

"It is an honor to join Celltrion Healthcare, which is leading the global bio industry," Nusbickel said. "Based on the experience and know-how accumulated over a long period, I will actively utilize Celltrion Healthcare's product competitiveness to show tangible results that can lead Celltrion Healthcare's growth in the U.S. market."